S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NYSE:CRL

Charles River Laboratories International - CRL Stock Forecast, Price & News

$250.35
-9.57 (-3.68%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$249.00
$258.11
50-Day Range
$201.94
$259.92
52-Week Range
$181.36
$349.84
Volume
411,316 shs
Average Volume
484,504 shs
Market Capitalization
$12.74 billion
P/E Ratio
29.49
Dividend Yield
N/A
Price Target
$297.38

Charles River Laboratories International MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.79 Rating Score
Upside/​Downside
18.8% Upside
$297.38 Price Target
Short Interest
Healthy
2.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
1.19mentions of Charles River Laboratories International in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.22 M Sold Last Quarter
Proj. Earnings Growth
4.50%
From $10.89 to $11.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

149th out of 1,028 stocks

Commercial Physical Research Industry

3rd out of 16 stocks

CRL stock logo

About Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment consists of the commercial production and sale of research models, research products, and the provision of services related to the maintenance and monitoring of research models and the management of the clients' research operations. The Discovery and Safety Assessment segment offers integrated drug discovery services directed at the identification, screening, and selection of a lead compound for drug development and offers safety assessment services, including bioanalysis, drug metabolism, pharmacokinetics, toxicology, and pathology. The Manufacturing Support segment consists of Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services, Biologics Solutions, which performs specialized testing of biologi

Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Stock News Headlines

Charles River Laboratories Acquires SAMDI Tech
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Charles River Labs
Here's Why You Should Retain Charles River (CRL) Stock Now
Charles River (CRL) Benefits From Price Rise Amid FX Woe
16 Large-Cap Stocks with Insider Buying
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
See More Headlines
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Company Calendar

Last Earnings
11/02/2021
Today
2/05/2023
Next Earnings (Estimated)
2/15/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
15986410
Employees
20,000
Year Founded
1947

Price Target and Rating

Average Stock Price Forecast
$297.38
High Stock Price Forecast
$420.00
Low Stock Price Forecast
$240.00
Forecasted Upside/Downside
+18.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

Net Income
$390.98 million
Pretax Margin
14.33%

Debt

Sales & Book Value

Annual Sales
$3.54 billion
Cash Flow
$15.19 per share
Book Value
$50.29 per share

Miscellaneous

Free Float
50,319,000
Market Cap
$12.74 billion
Optionable
Optionable
Beta
1.33

Social Links


Key Executives

  • James C. FosterJames C. Foster
    Chairman, President & Chief Executive Officer
  • Birgit GirshickBirgit Girshick
    Chief Operating Officer & Executive Vice President
  • Flavia H. Pease
    Chief Financial Officer & Executive Vice President
  • Arthur C. Hubbs
    Chief Information Officer & Senior Vice President
  • Barbara j. Patterson
    Senior VP-Regulatory Affairs & Compliance













CRL Stock - Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRL shares.
View CRL analyst ratings
or view top-rated stocks.

What is Charles River Laboratories International's stock price forecast for 2023?

14 Wall Street research analysts have issued 1-year price objectives for Charles River Laboratories International's stock. Their CRL share price forecasts range from $240.00 to $420.00. On average, they predict the company's stock price to reach $297.38 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts price targets for CRL
or view top-rated stocks among Wall Street analysts.

How have CRL shares performed in 2023?

Charles River Laboratories International's stock was trading at $217.90 at the start of the year. Since then, CRL stock has increased by 14.9% and is now trading at $250.35.
View the best growth stocks for 2023 here
.

When is Charles River Laboratories International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our CRL earnings forecast
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) posted its quarterly earnings data on Tuesday, November, 2nd. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.58 by $0.12. The medical research company had revenue of $895.90 million for the quarter, compared to analyst estimates of $902.03 million. Charles River Laboratories International had a net margin of 11.54% and a trailing twelve-month return on equity of 20.93%. The business's quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the business posted $2.33 earnings per share.
Read the conference call transcript
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $10.80-$10.95 for the period, compared to the consensus estimate of $10.80. The company issued revenue guidance of $3.89 billion-$3.93 billion, compared to the consensus revenue estimate of $3.89 billion.

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (2.26%), Congress Asset Management Co. MA (0.89%), Montrusco Bolton Investments Inc. (0.87%), Riverbridge Partners LLC (0.59%), Fisher Asset Management LLC (0.49%) and Strs Ohio (0.39%). Insiders that own company stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Shannon M Parisotto, Stephen D Chubb, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends
.

How do I buy shares of Charles River Laboratories International?

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $250.35.

How much money does Charles River Laboratories International make?

Charles River Laboratories International (NYSE:CRL) has a market capitalization of $12.74 billion and generates $3.54 billion in revenue each year. The medical research company earns $390.98 million in net income (profit) each year or $8.49 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

The company employs 20,000 workers across the globe.

Does Charles River Laboratories International have any subsidiaries?
The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..
Read More
How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The official website for the company is www.criver.com. The medical research company can be reached via phone at (781) 222-6000, via email at askcharlesriver@crl.com, or via fax at 978-988-5665.

This page (NYSE:CRL) was last updated on 2/5/2023 by MarketBeat.com Staff